NR2E3 and adrenal cortex carcinoma: Based on clinically frequently observed RNR-mediated G resistance and looking for potential therapeutic molecular targets, we evaluated, in a next step, the basal expression status of the RNR subunits (RRM1 and RRM2) in ACC patient samples.